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Objective: To examine predictors of patient perceived relevance of different diabetes 
  medication benefits, and to determine how medication benefit ratings of an inhaled insulin were 
associated with evaluation of, and interest in that inhaled insulin.
Methods: The study was an Internet survey of a US sample (n = 1094) of adults with type 2 
diabetes using different medication regimens. Patients were given a brief description of potential 
clinical benefits and administration procedures for the inhaled insulin described in this study 
(based on MannKind Corporation’s Technosphere insulin). Measures included indicators of 
medication benefits, needs and relevance, benefit ratings and overall evaluation of the studied 
inhaled insulin relative to current medication, and interest in the study medication. Multivariate 
regression assessed significant (P , 0.05) independent associations, controlling for demographic 
and disease characteristics.
Results: Relevance of potential medication benefits (avoidance of hyperglycemia, hypoglyce-
mia, weight gain, discomfort/inconvenience) was significantly associated with objective and 
subjective indicators of patients’ needs. Most need indicators were associated only with the 
specific benefit to which they apply; concerns about weight and lifestyle were associated with 
multiple benefits. Ratings of the studied inhaled insulin for avoiding postprandial hyperglycemia 
and discomfort/inconvenience were associated with overall evaluation of and interest in the 
inhaled insulin described in this study; rating of this medication for avoiding weight gain was 
associated with overall evaluation ratings.
Conclusions: Relevance of different potential benefits was based on objective and subjective 
indicators of need. Perceived efficacy of the inhaled insulin described in this study for avoiding 
postprandial hyperglycemia and discomfort/inconvenience were the benefits most strongly related 
to the evaluation of and interest in this medication.
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Introduction
“Drugs don’t work in patients who don’t take them”. A World Health Organization 
report on adherence to treatments reinforces this statement by C Everett Koop, former 
Surgeon General of the United States.1 On average, half the patients prescribed drugs 
for conditions common to people with diabetes (hyperglycemia, hypertension, hyper-
cholesterolemia) stop taking them after 1 year. Thus, it is critically important to better 
understand several aspects of patients’ diabetes medication use: adoption (filling an 
initial prescription), adherence (taking medication at prescribed dosage and frequency), Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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intensification (taking medication in larger doses or more 
frequently), and persistence (continuing treatment by   refilling 
prescriptions).
Studies of these aspects of medication use are limited 
(with the exception of adherence). One study found that 
adoption (first-fill) rates for diabetes medication was 85%, 
with lower rates for second-line oral agents and insulin.2 
A systematic review of medication adherence and persistence 
found that patients with type 2 diabetes took 67%–85% of 
their oral medication doses and 62%–64% of their insulin 
doses as prescribed, and that 36%–93% of patients remained 
on treatment for 6–24 months.3 Several factors are associ-
ated with medication adherence and persistence, including 
patients’ perception of medication benefits, side effects, and 
regimen complexity, as well as emotional well-being.4
Medication adoption is clearly the critical juncture in 
medication use; patients cannot adhere, intensify, or persist 
in using a medication they do not initiate. Physician recom-
mendations appear to play an important role in patients’ 
adoption of diabetes therapies.5 However, medication adop-
tion may be the result of a complex interplay of physician 
recommendations and patient requests for medication,6,7 and 
patient perceptions of treatment benefits play a role in their 
acceptance of physician treatment recommendations.5
We propose that two processes are key to better under-
standing patient adoption of diabetes therapies: 1) what 
determines the relevance of particular medication benefits 
to patients, and 2) what benefits are important to patients 
in comparing which of the relevant medications they 
will choose/accept. Note that these are functions of what 
patients perceive and how those perceptions factor into their 
  decisions. When making an initial decision about medication 
adoption, patients do not have a personal experience with any 
medication they have not already used themselves, but they 
do know what their current situation is, so their perceived 
needs may play a critical role in the adoption process.
Few studies explicitly examine the correlates of the 
importance or relevance of potential medication benefits, 
but some studies have implications for this issue. One study 
found that adoption rates for diabetes medication were 
higher for those with higher A1c levels, indicative of greater 
need for the medication.2 Another study found that among 
insulin-naïve patients, those with higher levels of need (poor 
control, more complications and diabetes distress) had a 
greater belief in the efficacy of insulin therapy.8 Thus, we 
hypothesize that subjective and objective factors indicative 
of need for a medication and the benefits it provides will 
be associated with the relevance of that medication benefit.
Several studies have examined how perceptions of specific 
diabetes therapy benefits are associated with overall ratings 
of treatment satisfaction or preference, and with adherence to 
or adoption of a given therapy. Use of an insulin pen rather 
than vial and syringe was associated with the perception 
that pens are better than vial and syringe for convenience/
flexibility, facilitating self-care, and clinical efficacy.5,9 
Perceiving pump therapy as more clinically efficacious and 
contributing more to psychological well-being than multiple 
daily insulin injection (MDI) therapy was associated with 
overall preference for pump therapy.10 The perceived effects 
of pramlintide therapy (eg, glucose control, hypoglycemia 
prevention, flexible eating, appetite control) were associated 
with treatment satisfaction and preference.11
When looking specifically at the adoption of insulin 
therapy, resistance to initiating insulin therapy is common.8 
Injection related problems are associated with being less will-
ing to take more frequent insulin injections12 and more frequent 
omission of insulin injections.13 The use of inhaled insulin has 
been shown to increase patients’ positive perceptions of insulin 
treatment14 and the availability of inhaled insulin increases 
patients’ willingness to initiate insulin therapy.15
Based on this research we propose to examine four 
potential benefits of an inhaled insulin – avoidance of   
a) postprandial hyperglycemia, b) hypoglycemia, c) weight 
gain, and d) discomfort/inconvenience. Specifically, we will 
examine: 1) factors associated with the relevance to patients 
of these perceived benefits, and 2) how ratings of these per-
ceived benefits for an inhaled insulin (compared to patients’ 
current therapy) are associated with overall assessment of 
that medication, including interest in using that medication 
if it were available. Based on earlier research, we hypothesize 
that: 1) patient characteristics indicating need for a particular 
benefit will be most strongly associated with the relevance of 
the corresponding benefit – a) perceived glucose control and 
frequency of hyperglycemia with the importance of avoiding 
hyperglycemia, b) frequency and fear of hypoglycemia with 
the importance of avoiding hypoglycemia, c) weight and 
weight worry with the relevance of avoiding weight gain, and 
d) concern about injections with the importance of avoiding 
discomfort and inconvenience; 2) among potential medica-
tion benefits, clinical efficacy (avoiding hyperglycemia) and 
avoiding injection-related discomfort and inconvenience will 
be the benefits most strongly associated with higher ratings 
of and interest in using the inhaled insulin described in this 
study. This study examines these issues among adult patients 
with type 2 diabetes using different treatment regimens, 
including oral agents only, basal insulin, and MDI therapy.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
257
Modeling patient interest in inhaled insulin
Methods
Harris Interactive developed the questionnaire in   cooperation 
with MannKind Corporation and the authors of this paper; 
Synovate Consumer Opinion Panel secured the study 
sample and programmed and fielded the survey. The Human   
Subjects Research Committee at Loyola University   Maryland 
approved the study protocol and use of the data from the 
project. Partial results of this study have been reported 
elsewhere.16
The sampling plan was designed to generate a sample that 
was nationally representative of the diagnosed diabetes popu-
lation, based on the 2005 National Health Interview Study 
according to gender, age, ethnicity, geographic region, and 
income. Targets for type of diabetes and diabetes treatment 
regimen were selected based on the 2007 US Market Study 
of the Roper Global Diabetes Program. Only those who had 
indicated that they had diabetes upon enrolling in the   Synovate 
consumer panel were recruited for participation. Data were 
then weighted to diabetes population proportions.
The study population for this analysis was adult individu-
als who self-reported physician-diagnosed type 2 diabetes. 
  Exclusion criteria included: using an insulin pump, taking an 
injected medication other than insulin, having used inhaled 
insulin, not taking diabetes medication, or having lung prob-
lems (asthma, reduced lung capacity, any treated lung disease, 
smoking   history). The study population consisted of 1094 
respondents, 734 who took only oral medications to control 
blood glucose, 228 who took basal insulin (with or without 
oral medications) to control blood glucose, and 132 patients 
who used multiple daily insulin injections (see Table 1). 
Patients were almost evenly divided by sex, with the major-
ity (78%) being white. The average age was 57 years and the 
average annual income was about US$51,000. The majority of 
respondents had health insurance (94%) and saw a primary care 
physician for their diabetes care (82%). Patients had an aver-
age diabetes duration of 10 years. On average the population 
was overweight/obese (BMI = 36 m/kg2) and had a moderate 
number of comorbidities (∼2). Self-reported medication-taking 
for depression was moderately prevalent (19%).
Potential study participants received an email message 
inviting them to participate in an Internet survey, stating that 
the survey would take 10 minutes to complete, offering incen-
tives (points toward merchandise or gift cards, entry into a 
sweepstakes, highlights of the survey results), and providing a 
link to the study survey. After agreeing to participate, respon-
dents answered questions about demographic, disease and 
health care characteristics, and health-related beliefs. Partici-
pants were then given a description of the study medication 
(see Appendix 1), after which they assessed this medication 
(see Measures below). The description was developed by the 
study sponsor (MannKind) based on studies of Technosphere 
inhaled insulin, indicating the potential pharmacological 
and clinical benefits17–20 and the then-current procedure for 
storage, maintenance, and use of the medication and device 
(subsequently simplified following results of patient use 
studies and product development), along with a picture of the 
inhaler in use at the time of the study (subsequently replaced 
with a smaller device).
Measures
In addition to a variety of demographic and health care 
characteristics, the study included measures of several 
indicators of objective need for medication benefits, including 
frequency of high blood glucose (for avoiding hyperglycemia), 
frequency of low blood sugar (for avoiding hypoglycemia), 
and weight/BMI (for avoiding weight gain). The study also 
included subjective measures (described below) of: health-
related beliefs; relevance to the patient of potential benefits 
of the studied inhaled insulin; assessments of the study 
medication compared to the patient’s current treatment; and 
  interest in this medication (see Appendix 2).
health-related beliefs
The questionnaire incorporated questions regarding health-
related beliefs; there were six response options ranging from 
agree completely to disagree completely (scored 100 to 0, 
with reverse scoring where appropriate). Items were selected 
to represent several dimensions of subjective need for poten-
tial medication benefits. Reliability analyses were conducted 
to identify items within each measure that lowered inter-item 
agreement; these items were deleted. The analysis resulted in 
four measures, with each multi-item measure calculated as 
the mean of component items: negative perceptions of injec-
tions (5 items, alpha = 0.74), treatment restrictions on lifestyle 
(2 items, alpha = 0.71), weight worry (4 items, alpha = 0.74), 
fear of hypoglycemia (1 item). Another measure represent-
ing perceived lack of diabetes control was calculated as 
the mean of three items based on 10-point response scales 
scored 100 to 0, with higher scores indicating worse control 
(alpha = 0.71).
Relevance of medication benefits
There were four single-item measures, each indicating how 
relevant one of the following benefits was to the patient: avoid-
ing high blood sugar after meals, avoiding low blood sugar, 
avoiding weight gain, avoiding discomfort and   inconvenience. Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Table 1 Sample profile by medication group
Measures Oral only 
(n = 734)
Basal insulin 
(n = 228)
MDI 
(n = 132)
Total 
(n = 1094)
Demographics
Age (years) 57.0 ± 10.7 58.5 ± 9.3 57.7 ± 11.4 57.4 ± 10.5
Female 47.1 (346) 57.0 (130) 59.1 (78) 50.6 (554)
Race/ethnicity
  White 75.6 (555) 79.4 (181) 85.6 (113) 77.6 (849)
  Black 11.7 (86) 10.5 (24)   9.8 (13) 11.2 (123)
  hispanic   9.3 (68)   7.0 (16)   2.3 (3)   8.0 (87)
  Other race   3.4 (25)   3.1 (7)   2.3 (3)   3.2 (35)
education*   5.2 ± 1.7   5.0 ± 1.6   4.8 ± 1.7   5.1 ± 1.6
income (thousands of $)** 53.4 ± 36.0 46.5 ± 33.1 46.0 ± 38.2 51.1 ± 35.8
Health care
Health care provider***
  PcP 87.3 (641) 78.9 (180) 60.9 (81) 82.4 (902)
  endocrinologist   9.9 (73) 19.7 (45) 34.6 (46) 15.0 (164)
  Other hcP   2.7 (20)   1.3 (3)   4.5 (6)   2.6 (29)
Health insurance*
  no insurance   7.1 (52)   4.8 (11)   3.8 (5)   6.2 (68)
  Private insurance 71.4 (525) 64.8 (147) 66.2 (88) 69.4 (760)
  Medicare insurance   8.8 (65) 14.1 (32) 12.0 (16) 10.3 (113)
  Military insurance   7.1 (52)   7.9 (18)   6.8 (9)   7.2 (79)
  Medicaid insurance   5.6 (41)   8.4 (19) 11.3 (15)   6.8 (75)
Disease
Pen use***   0 (0) 23.2 (53) 40.2 (53)   9.7 (106)
Duration of DM***   8.1 ± 7.1 13.4 ± 8.6 15.6 ± 10.0 10.1 ± 8.3
Hypoglycemia***
  nA 10.9 (80)   4.8 (11)   1.5 (2)   8.5 (93)
  none 36.6 (269) 18.9 (43) 15.2 (20) 30.3 (332)
  Occasionally 46.7 (343) 67.0 (152) 69.7 (92) 53.7 (587)
  Frequently   5.9 (43)   9.3 (21) 13.6 (18)   7.5 (82)
Hyperglycemia***
  nA 10.9 (80)   4.8 (11)   1.5 (2)   8.5 (93)
  none 19.2 (141) 12.7 (29)   6.8 (9) 16.4 (179)
  Occasionally 50.7 (372) 48.7 (111) 43.2 (57) 49.4 (540)
  Frequently 19.2 (141) 33.8 (77) 48.5 (64) 25.8 (282)
BMi*** 35.2 ± 8.0 37.6 ± 9.6 37.1 ± 9.5 35.9 ± 8.6
nr of comorbidities***   1.9 ± 1.2   2.2 ± 1.3   2.6 ± 1.6   2.1 ± 1.3
Depression (taking medication)*** 15.6 (115) 24.2 (55) 25.6 (34) 18.6 (204)
Beliefs
Poor DM control*** 30.8 ± 18.1 39.5 ± 17.7 40.2 ± 15.8 33.7 ± 18.2
hypoglycemia fear*** 38.2 ± 29.5 48.3 ± 28.8 49.8 ± 31.9 41.7 ± 30.1
Weight concern*** 50.9 ± 22.5 60.1 ± 24.5 65.5 ± 24.4 54.6 ± 24.0
negative injections*** 50.8 ± 22.1 28.6 ± 20.3 23.7 ± 19.6 42.9 ± 24.3
Treatment restrictions*** 32.8 ± 26.4 42.9 ± 27.2 41.9 ± 29.5 36.0 ± 27.3
Study medication benefit relevance
Avoid high Bg*** 68.1 ± 29.2 75.8 ± 24.3 77.3 ± 26.1 70.8 ± 28.1
Avoid low Bg*** 61.2 ± 31.5 69.6 ± 27.7 68.5 ± 30.9 63.8 ± 30.8
Avoid weight gain** 70.1 ± 30.9 74.8 ± 28.0 79.3 ± 27.6 72.2 ± 30.1
Avoid discomfort and inconvenience 65.6 ± 32.3 66.2 ± 29.3 65.0 ± 33.0 65.6 ± 31.3
Study medication benefit rating
Avoid high Bg*** 15.8 ± 21.1a 22.7 ± 19.6a 22.2 ± 20.3a 18.0 ± 20.9a
Avoid low Bg*** 13.6 ± 20.9a 21.0 ± 20.3a 19.8 ± 21.4a 15.9 ± 21.0a
Avoid weight gain*** 16.8 ± 22.5a 25.7 ± 20.5a 23.9 ± 21.4a 19.5 ± 22.2a
Avoid discomfort and inconvenience*** 17.8 ± 23.7a 25.0 ± 22.2a 24.2 ± 22.4a 20.1 ± 23.4a
Study medication assessment
comparison to current medication*** 15.3 ± 25.2a 25.7 ± 21.7a 26.8 ± 20.9a 18.9 ± 24.6a
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Table 1 (Continued)
Measures Oral only 
(n = 734)
Basal insulin 
(n = 228)
MDI 
(n = 132)
Total 
(n = 1094)
interest in using 67.2 ± 27.6 69.9 ± 28.7 73.2 ± 27.9 68.5 ± 27.9
impact on insulin initiation 28.7 ± 23.1 nA nA 28.7 ± 23.1
Notes: education: 1 = less than high school, 2 = completed some high school, 3 = high school graduate or equivalent, 4 = trade school, 5 = completed some college, 6 = 
college graduate, 7 = completed some graduate work, 8 = completed graduate degree. cell entries are mean ± standard deviation or % (n). aMean is significantly (P , 0.001) 
different from rating of no difference from current medication (=0). *P , 0.05 for medication group differences; **P , 0.01 for medication group differences; ***P , 0.001 
for medication group differences.
Abbreviations: Bg, blood glucose; BMi, body mass index; DM, diabetes mellitus; hcP, health care provider; MDi, multiple daily insulin injection; nA, not ascertained;   
PcP, primary care provider.
There were five response options ranging from “extremely 
relevant” (=100) to “not at all relevant” (=0).
study medication assessment
There were seven single-item measures. Four measures 
compared the inhaled insulin described in this study to 
the patient’s current treatment, one item for each of four 
potential benefits: avoiding high blood sugar after meals, 
avoiding low blood sugar, avoiding weight gain, avoiding 
discomfort and inconvenience. There were five response 
options ranging from the study medication being “much 
better” (=50) to “much worse” (=−50) with a midpoint of 
“about the same” (=0). There was also an item that asked for 
an overall evaluation comparing the studied inhaled insulin 
to the patient’s current treatment, with identical response 
options and scoring.   Interest in using the study medication, 
if it were to become available, was rated using a 5-point scale 
from “extremely interested” (=100) to “not at all interested” 
(=0). Impact of the availability of the study medication on 
willingness to initiate insulin use (asked only among those 
not currently using insulin) was assessed with a 5-point 
response scale ranging from “much more willing” (=50) to 
“much less willing” (=−50), with a midpoint of “neither more 
or less willing” (=0).
statistical analysis
All study measures were compared among the three medi-
cation groups: oral medication only, basal insulin (with 
or without oral medication), and multiple daily injections 
(MDI). Chi-square was used for categorical variables, and 
ANOVA was used for continuous variables.
Analysis of the correlates of benefit relevance, interest in 
using the inhaled insulin described in this study, and overall 
assessment comparing the medication used in this study 
with current treatment used ordinary least squares multiple 
regression. All correlates were forced into the model to 
control for potential confounding and assess the independent 
contribution of each factor to the explanatory models.
Results
Health-related beliefs were neither extremely positive nor 
extremely negative; on a scale of 0 to 100, means ranged 
between 23 and 66 (see Table 1). All four study medication 
benefits were rated as relevant with means ranging from 61 
to 80. The studied inhaled insulin was rated significantly 
better than the patients’ current treatments for all benefits 
in all groups (means between 13 and 26 where 0 represents 
no difference and the range is 50 to −50). Using the same 
scale, the study medication was rated better overall than 
current treatment by all medication groups (means between 
15 and 27), and all medication groups indicated an interest 
in using the studied inhaled insulin (means between 67 and 
74 on a scale of 0 to 100). Respondents taking only oral dia-
betes medication indicated that the availability of the study 
medication would substantially increase their willingness to 
initiate insulin treatment (mean of 29 where 0 represents no 
difference and the range is 50 to −50).
Table 2 presents the correlates of benefit relevance (for 
avoiding: high blood sugar after meals, low blood sugar, 
weight gain, discomfort/convenience), the overall assessment 
of the inhaled insulin described in this study compared to 
current treatment, and interest in using this drug. Significant 
correlates of benefit relevance included a number of demo-
graphic, disease, and health care provision characteristics. 
Each benefit relevance measure was significantly associated 
with one or more demographic and disease characteristics. 
Although medication groups differed on three of four rel-
evance measures, these differences disappeared when all 
other factors were controlled.
All factors indicating need for a particular benefit were 
associated with the relevance of that benefit; avoiding 
postprandial hyperglycemia was associated with more fre-
quent hyperglycemia and worse perceived diabetes control; 
avoiding hypoglycemia was associated with more frequent 
hypoglycemia and fear of hypoglycemia; avoiding weight 
gain was associated with higher BMI and more weight 
worry; avoiding discomfort/inconvenience was associated Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Table 2 Correlates of benefit relevance ratings, interest in study medication, and comparison of study medication to current medicationa
Correlate Relevance  
of avoiding  
high BG
Relevance  
of avoiding  
low BG
Relevance  
of avoiding  
weight gain
Relevance of  
avoiding discomfort  
and inconvenience
Compare study  
medication to  
current medication
Interest  
in study  
medication
Demographics
Age (years) −0.022 0.023 −0.039 0.004 0.051 0.028
Female 0.078* 0.094** 0.099*** 0.097** 0.013 −0.029
Blackb 0.048 0.085** 0.044 0.079* 0.043 −0.023
hispanicb 0.046 0.070* 0.042 0.054 0.090*** 0.047
Other raceb 0.000 0.006 −0.012 0.003 0.045 0.020
education 0.045 0.016 0.067* 0.050 −0.060* 0.011
income 0.028 0.028 0.046 −0.012 0.060* 0.072*
Health care
endocrinologiste −0.010 −0.024 −0.029 −0.037 −0.016 −0.051
Other hcPe −0.070* −0.020 −0.057* −0.039 −0.022 −0.014
no insurancef −0.004 −0.008 0.024 −0.001 0.046 0.040
Medicare insurancef −0.006 −0.021 −0.032 −0.045 0.010 −0.059
Military insurancef −0.023 −0.041 0.010 0.022 0.008 −0.046
Medicaid insurancef 0.041 0.022 0.008 0.029 0.039 0.039
Disease
Basal insulinc 0.026 0.034 −0.006 0.029 0.023 −0.034
MDic 0.010 0.000 0.011 0.009 0.028 0.016
Pen use 0.061 0.021 0.035 0.055 0.039 0.019
Duration of DM −0.032 −0.028 0.027 −0.041 0.008 0.014
BMi (log) −0.052 −0.058 0.073* −0.004 0.018 −0.002
nr of comorbidities 0.028 0.004 0.054 0.093** 0.032 0.048
Depression 0.031 −0.001 0.042 −0.043 −0.013 0.028
hypoglycemia  
(occasionally)d
0.001 0.154*** 0.026 0.004 0.014 −0.056
hypoglycemia  
(frequently)d
−0.018 0.150*** 0.034 −0.010 −0.030 −0.040
hyperglycemia  
(occasionally)d
0.149*** −0.055 0.000 −0.016 0.075* 0.045
hyperglycemia  
(frequently)d
0.205*** −0.012 0.056 0.057 0.117** 0.038
Beliefs
Poor DM control 0.120*** 0.053 0.009 0.038 0.075* 0.050
hypoglycemia fear 0.001 0.217*** −0.029 0.035 −0.009 −0.013
Weight concern 0.128*** 0.073* 0.344*** 0.064 0.024 0.068*
negative injections −0.012 −0.036 0.001 0.174*** −0.011 0.026
Treatment restrictions 0.095** 0.055 −0.011 0.087* 0.143*** 0.040
Benefits
Avoid high Bg 0.196*** 0.188***
Avoid low Bg 0.009 0.046
Avoid weight gain 0.127** 0.074
Avoid discomfort  
and inconvenience
0.174*** 0.224***
R-squared 0.165 0.166 0.241 0.125 0.381 0.301
Notes:  aCell entries are standardized regression coefficients;  bReference category = White;  cReference category = Oral medication only;  dReference category = no 
hypoglycemia or hypoglycemia; eReference category = PcP; fReference category = Private insurance. *P , 0.05; **P , 0.01; ***P , 0.001.
Abbreviations: Bg, blood glucose; BMi, body mass index; DM, diabetes mellitus; hcP, health care provider; MDi, multiple daily insulin injection; nA, not ascertained;   
PcP, primary care provider.
with more perceived treatment restrictions and more nega-
tive perceptions of injection. Two subjective indicators of 
need were associated with relevance of a benefit other than 
hypothesized – treatment restrictions were associated with 
relevance of avoiding hyperglycemia, and weight worry 
was associated with relevance of avoiding hyperglycemia 
and hypoglycemia.
Table 2 also presents the associations with overall evalu-
ation of and interest in the studied inhaled insulin. Several 
demographic and health care factors were significantly Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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associated with one or both of these overall assessment 
measures. Other than perceived medication benefits, the fac-
tors most strongly associated with overall assessment were 
indicators of need: those with more frequent hyperglycemia, 
more poorly controlled diabetes, and more perceived treat-
ment restrictions rated the inhaled insulin described in this 
study more positively compared to their current treatment; 
those with more weight worry were more interested in the 
study medication.
Although all medication benefits had significant relation-
ships to both overall assessment measures prior to their entry 
into the model, when entered together to assess independent 
associations, some became nonsignificant. Only avoiding 
high blood sugar after meals and avoiding discomfort and 
inconvenience remained significantly associated with both 
interest in and overall evaluation of the study medication; 
avoiding weight gain remained significantly associated with 
overall evaluation of the study medication.
Discussion
This study’s findings indicate that a number of demographic 
characteristics, health care provision factors, disease charac-
teristics, and health-related beliefs are significantly associated 
with the relevance of several potential benefits and overall 
assessment of the inhaled insulin examined in this study. This 
study yields several findings regarding correlates of diabetes 
medication benefit relevance:
First, the relevance of potential medication benefits is 
independently related to each of the categories of factors 
examined in the study – patient demographic character-
istics, disease traits and experiences, and health-related   
beliefs.
Second, the relevance of several potential benefits of dia-
betes medications tends to vary consistently with a number of 
patient characteristics. That is, any given factor (eg, female 
sex) tends to be associated in the same direction, albeit to a 
greater or lesser degree, with the relevance of each benefit 
examined.
Third, the strongest correlates of the relevance of a benefit 
are the objective and subjective indicators of need for that 
benefit. Moreover, few of the need factors were associated 
with the salience of a benefit other than that for which it 
indicates need. Thus, these associations exhibit both sensi-
tivity and specificity. Weight worry and treatment-related 
restrictions of lifestyle were the only need factors associated 
with other benefit relevance measures; this is consistent with 
research suggesting that these factors may be indicators of 
global health-related distress.9,21,22
The study also yields several findings regarding correlates 
of overall assessment of the study medication compared 
to patients’ current treatment. First, the findings generally 
  parallel those reported above for benefit relevance; the   overall 
assessment measures are independently related to every cat-
egory of factor examined in the study, and they tend to vary 
consistently with patient characteristics.
Second, both objective and subjective factors indicative 
of need for medication benefits are associated with overall 
assessment of the inhaled insulin described in this study, 
even when ratings of the benefits of that medication are 
controlled. This study replicates earlier research suggesting 
that weight worry21 and negative attitudes toward insulin22 
may be important factors in a variety of patient decisions and 
actions related to diabetes medication, and is consistent with 
findings in this study regarding generalized associations of 
these factors with benefit relevance.
Third, among the benefit ratings, only avoiding high 
blood sugar after meals and discomfort/inconvenience have 
consistently strong independent relationships with overall 
assessment of the study medication; avoiding weight gain has 
a weaker and less consistent, albeit significant, independent 
relationship.
Taken together, these two sets of findings help identify 
which medication benefits are most important to patients. 
Results suggest that patients will evaluate diabetes medica-
tions primarily in terms of their ability to control postprandial 
hyperglycemia and reduce discomfort and inconvenience. 
These results replicate and extend those of a recent study 
demonstrating that perceived control of postprandial glucose 
levels was the strongest predictor of overall assessment of 
another diabetes medication.11 That study was not able to 
examine the impact of comfort/convenience on medication 
assessment, but the current study indicates that this factor 
may have an impact of roughly the same size as efficacy in 
controlling postprandial hyperglycemia.
In earlier studies we found that the impact of conve-
nience on facilitating better self-care was a major factor 
in patients’ and physicians’ decisions about initiation of 
diabetes treatment.5,7 While the current study did not dis-
tinguish between convenience for its own sake and conve-
nience that makes better self-care possible, it is important 
to recognize that these factors are closely related. More-
over, if patients do not agree to initiate and sustain use of 
a medication, that medication will not be used no matter 
how clinically efficacious it is. Thus, convenience should 
not be dismissed as unimportant from a clinical or payer   
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Our study did not identify an association between overall 
assessment of the study medication and its relative efficacy in 
avoiding hypoglycemia. Does this mean that   hypoglycemia 
does not play a role in patients’ diabetes medication   decisions? 
We think not, because studies have shown concerns about 
hypoglycemia to be a major factor in patients’ medication 
related decisions.23,24 It may be that the medication description 
used in this study did not convince patients that the study 
medication would be effective in avoiding hypoglycemia; 
indeed the rating for this benefit (compared to current treat-
ment) was lower than other potential benefits. It remains to 
be seen whether beliefs about hypoglycemia are resistant to 
change, or whether patients require either a) a more effective 
explanation of the ways that a medication might help avoid 
hypoglycemia or b) actual experience of changes in the level 
of hypoglycemia.
Respondents not currently taking insulin indicated that 
the availability of the study inhaled insulin would reduce 
the barriers to initiation of insulin therapy. This finding 
should be viewed with caution as it may involve a dis-
crepancy between word and deed. However, a randomized 
controlled trial to examine the impact of availability of 
an inhaled insulin showed an increase in the initiation of 
insulin therapy.25 Yet it remains to be determined whether 
the availability of the study inhaled insulin would have an 
effect on initiation of insulin therapy in a real-world setting. 
Answering this question will depend on whether an inhaled 
insulin is brought to market, a possibility that is not certain 
at this point in time.
study strengths and limitations
The strengths of this study include the large and diverse 
sample, and the extensive collection of measures that could 
be examined and controlled. One weakness of the study is the 
lack of variation in the description of medication benefits.26 
Thus, it was not possible to test trade-offs among these 
benefits, nor whether these same benefits would influence 
preference for other methods of insulin administration or 
other insulin formulations. However, the study did assess the 
benefits thought to be realistic for a given medication (Tech-
nosphere insulin) as compared to other medications that were 
actually being used or available for use by patients.18 It is not 
possible to know how a given medication might be described 
by any actual clinician in discussing initiation of that medica-
tion with an individual patient, so this is an inherent limitation 
of any study that does not either specify or measure the clini-
cian’s actions. Physicians’ explanations and recommendations 
may influence or override patients’ initial preferences for a 
particular medication, and thus are a crucial contextual factor 
in the study of patient preferences. Thus, it is important to 
understand how physicians (and other professionals involved 
in decisions about diabetes   medications) perceive inhaled 
insulin and how they would present this therapeutic option to   
patients.27
This study not only assessed the impact of perceived 
clinical efficacy (hyperglycemia avoidance) on medication 
preference, it also assessed the impact of the most clinically 
significant common side effects of insulin therapy (hypogly-
cemia, weight gain). One major nonclinical consideration 
not examined in this study is the impact of cost on medica-
tion preference. Cost can play a major role in medication 
preference, especially when the effective cost to the patient 
(taking into account the patient’s health care coverage) varies 
between medications. However, a consideration of the impact 
of cost under different insurance coverages or health care 
policies was beyond the scope of the present study.
clinical implications
Patients may choose their diabetes medications based on 
the benefits identified here – avoiding high blood glucose 
and discomfort/inconvenience, so it is important not to 
underestimate the demands made by the treatment regimen; 
uncomfortable and inconvenient treatments may be rejected 
by patients even if they are effective. Respondents not taking 
insulin in this study indicated that they would be more will-
ing to initiate insulin therapy if a more convenient insulin 
delivery system that provided good glucose control were 
available. Additionally, patients may have better medication 
adherence and maintenance and be more willing to intensify 
treatment with such a system (although we did not examine 
these possibilities in the current study). Finally, this study 
suggests that the benefits perceived to characterize the study 
medication may also improve patient outcomes if they could 
be achieved by other insulin formulations or administration 
methods.
Research implications
We need additional research to examine the benefit pro-
files of different medications and the trade-offs patients 
make in choosing medications. The ultimate goal of 
such research should be to determine whether these ben-
efit profiles affect real-life decisions and actions, such 
as medication initiation, adherence, intensification, and   
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Appendix 1
survey description of study inhaled 
insulin
Brand X is a new type of insulin designed for treatment of type 
1 or type 2 diabetes in adults. For type 1 diabetes, Brand X 
should be used in combination with a long-acting (basal) 
insulin. For type 2 diabetes, Brand X can be used alone instead 
of rapid-acting or regular human insulin, or combination 
with either oral medications or long acting insulins. Use of 
Brand X is not recommended for patients who have asthma, 
poorly controlled lung disease, or who smoke. Brand X has 
a unique method of action that lets it work faster than current 
insulins, to more quickly bring your blood sugar back into the 
normal range after your meal. Because of its speed of action, 
Brand X has also shown: A greatly reduced incidence of severe 
hypoglycemia (low blood sugar) compared to currently avail-
able mealtime insulins; no weight gain was observed among 
patients in long-term clinical trials using Brand X insulin.
Brand X comes in a dry powder form of insulin that is 
inhaled at the start of a meal, using a palm-sized inhaler. The 
dry powder turns into a liquid when it enters the lungs for easy 
absorption into the blood stream. It comes in small cartridges 
containing a single premeasured dose, which are inserted in 
the inhaler before use. Each individual cartridge requires two 
inhalations. The insulin has a total shelf life of 18 months 
when refrigerated. The insulin is stable at room temperature 
for 3 months. The mouthpiece needs to be cleaned every 2 
weeks.
Appendix 2
Question wording for subjective survey 
measures
Scoring of responses for belief items (100 = Agree 
completely, 80 = Agree somewhat, 60 = Agree slightly, 
40 = Disagree slightly, 20 = Disagree somewhat, 0 = Disagree 
completely).
Negative perceptions of injections
–	 If I have to inject myself to give insulin, it is/would be no 
big deal (Reverse Scored)
–  I am not/would not be comfortable with injecting myself 
to give myself insulin
–  Having to take shots is the biggest drawback to taking 
insulin
–  I am/would be ok with one injection of insulin a day but 
I would never consider taking it more often
–   Insulin injections are/would be very painful
Treatment restrictions on lifestyle
–   I get so frustrated by my diabetes and the limits it puts 
on my lifestyle
–   Taking good care of my diabetes limits my daily 
flexibility
Weight worry
–   My doctor considers weight to be a major problem in 
keeping me from better managing my diabetes
–   I am very worried about gaining weight
–   Insulin causes weight gain
–   Diabetes has caused my weight to increase significantly
Fear of hypoglycemia
–   I worry a lot about having blood sugar lows
Poor diabetes control
–   How severe do you think your diabetes is?
  (100 = Less severe than others with diabetes…..0 = More 
severe than others with diabetes)
–   How well are you able to control your diabetes?
  (100 = Able to control extremely well…..0 = Not at all 
able to control)
–   How well do you follow-through on the treatment plan 
that your doctor has prescribed for your diabetes?
  (100 = Follow extremely closely…..0 =  Do  not 
follow at all)
Medication benefit relevance
Following is a list of benefits that Brand X could provide. 
Please rate how relevant each benefit is for you personally in 
your efforts to treat your diabetes. (100 = Extremely relevant, 
75 = Very relevant, 50 = Somewhat relevant, 25 = Not very 
relevant, 0 = Not at all relevant)
–   Avoiding high blood sugar after meals
–   Avoiding low blood sugar
–   Avoiding weight gain
–   Avoiding discomfort and inconvenience
Medication benefit rating
If Insulin User: How do the following benefits of Brand X 
compare to other insulin treatments currently on the market? 
If not Insulin User: How do the following benefits of Brand X 
compare to the medicine you currently take to manage your 
diabetes? (50 = Much better than other insulin treatments, 
25 = Somewhat better than other insulin treatments, 0 = About 
the same as other insulin treatments, −25 =   Somewhat worse 
than other insulin treatments, −50 = Much worse than other 
insulin treatments)Patient Preference and Adherence
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–   Avoiding high blood sugar after meals
–   Avoiding low blood sugar
–   Avoiding weight gain
–   Avoiding discomfort and inconvenience
Comparison to current medication
Overall, how would you compare Brand X to your current 
diabetes treatment plan? Brand X is…. (50 = Much better 
than my current diabetes treatment, 25 = Somewhat better 
than my current diabetes treatment, 0 = About the same as 
my current diabetes treatment, −25 = Somewhat worse than 
my current diabetes treatment, −50 = Much worse than my 
current diabetes treatment).
Interesting in using inhaled insulin
Having read about Brand X, how interested would you be 
in talking to your doctor about Brand X once it is available? 
If you are not currently on insulin, please consider your 
interest in Brand X if insulin becomes a therapy you are 
considering with your doctor. (100 = Extremely Interested, 
75 = Very Interested, 50 = Somewhat Interested, 25 = Not 
Very Interested, 0 = Not at All Interested).
Impact of inhaled insulin on insulin initiation
If your doctor said that you needed to start taking insulin, how 
would the availability of Brand X make you feel about start-
ing? (50 = I would be much more willing to start, 25 = I would 
be somewhat willing to start, 0 = I would be neither more nor 
less willing to start, −25 = I would be somewhat less willing 
to start, −50 = I would be much less willing to start).